New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment
Controlling the HIV epidemic: ambitious funding, expanded workforce, innovations and micro-focus needed
Dutch model finds PrEP for high-risk gay men is cost-effective at current prices and cost-saving at generic prices
German medicines watchdog rejects ‘new tenofovir’ pill
High Court rules NHS England is responsible for funding PrEP
PrEP rollout recipients in France top 1000: full trial results report 97% effectiveness
Gains in curbing HIV epidemic could be lost without continued commitment, AIDS 2016 speakers say
Progress towards 90-90-90 targets is promising, but funding is the critical step, says UNAIDS leader
